Contineum Therapeutics, Inc. Class A Common Stock (CTNM) is a Healthcare · Biotechnology company listed on NASDAQ. Price $13.53 (+2.42%), Market cap $0.50B, 52-week low–high $3.40 ~ $16.00.
Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing of small molecules different therapies for neuroscience, inflammation, and immunology indications in the United States. The company's lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and chronic pain. It also develops PIPE-307, a novel, small-molecule inhibitor of the muscarinic type 1 receptor for depression and relapse-remitting multiple sclerosis. The company was formerly known as Pipeline Therapeutics, Inc. and changed its name to Contineum Therapeutics, Inc. in November
Financial statements, price targets, institutional (13F) holdings and related news for Contineum Therapeutics, Inc. Class A Common Stock are updated in real time on BlackAll Trade.
Contineum Therapeutics, Inc. Class A Common Stock trades at $13.53 (+2.42%). Real-time quotes and charts are available on BlackAll Trade.
Contineum Therapeutics, Inc. Class A Common Stock has a market cap of about $0.50B.
Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing of small molecules different therapies for neuroscience, inflammation, and immunology indications in the